Biogen Idec and Genentech, Inc. have amended their antibody collaboration targeting CD20. Genentech will have responsibility for further development and commercialization of ocrelizumab in multiple sclerosis (MS), as well as all costs going forward. Biogen will receive royalties on U.S. sales of ocrelizumab. The companies have also agreed that the commercialization of ocrelizumab will not impact the current profit share of Rituxan (rituximab). Biogen will increase its share of the losses and ...